 Infliximab
"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 | | 2001 | 0 | 4 | 4 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 6 | 6 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 4 | 4 | | 2014 | 2 | 4 | 6 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 2 | 3 | | 2019 | 2 | 1 | 3 | | 2020 | 0 | 4 | 4 | | 2021 | 0 | 7 | 7 | | 2022 | 0 | 7 | 7 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Petr V, Tichanek F, Liu SL, Poppelaars F, Renner B, Laskowski J, Purohit S, Zhao M, Jalal D, Heeger PS, Thurman JM. Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction. Am J Transplant. 2025 Oct; 25(10):2173-2181.
-
Shunyakova J, Patnaik JL, Xia J, Hassman LM, Pecen PE, Palestine AG, Reddy AK. Immunomodulatory Therapy Discontinuation for Reasons Other Than Efficacy in the Treatment of Ocular Inflammation. Ocul Immunol Inflamm. 2025 Oct; 33(8):1807-1810.
-
Larson C, Berinstein JA, Tedesco N, Seidelin JB, Ovesen PD, Uzzan M, Amiot A, Nuzzo A, Laharie D, Constant BD, Albenberg L, El-Hussuna A, Bishu S, Cohen-Mekelburg S, Higgins PDR, Steenholdt C. Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2263-2271.e6.
-
Ishikawa T, Nishimura K, Okamoto N, Akamine K, Inoue N, Irabu H, Kato K, Keino H, Kojima M, Kubo H, Maruyama K, Mizuta M, Shabana K, Shimizu M, Sugita Y, Takakuwa Y, Takanashi S, Takase H, Umebayashi H, Umezawa N, Yamanishi S, Yamazaki K, Yashiro M, Yasumi T, Mori M. Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review. Mod Rheumatol. 2024 Dec 25; 35(1):174-184.
-
Lai JM, Milner DC, Frisbie R, Puente MA. Abducens nerve palsy: a rare copresenting sign of incomplete Kawasaki Disease. J AAPOS. 2025 Feb; 29(1):104061.
-
Liu A, Xuan A, Socal M, Anderson G, Anderson KE. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019. J Manag Care Spec Pharm. 2024 Jan; 30(1):15-21.
-
White S, Morrow R, Pan I, de Zoeten EF. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr. 2023 06; 76(6):701-703.
-
Kumar M, Harvey RN, Osei SK, Fatima A, Menning AZ, Akay B, Brahmamdam P, Stallion A, Novotny NM. The Evolving Effectiveness of Biologics in Avoiding Surgery in Children With Ulcerative Colitis: At what Nutritional Cost? Am Surg. 2023 Dec; 89(12):5584-5591.
-
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 12 01; 75(6):724-730.
-
Dolinger MT, Rolfes P, Spencer E, Stoffels G, Dunkin D, Dubinsky MC. Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions. J Crohns Colitis. 2022 Sep 08; 16(9):1420-1427.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|